We would like to ensure that you are still receiving content that you find useful – please confirm that you would like to continue to receive ILO newsletters.
18 September 2019
On 26 June 2019 the Federal Council submitted a draft amendment to the Narcotics Act (SR 812121) for consultation that aims to facilitate patients' access to cannabis-based treatments.
The revised act would allow patients to obtain direct medical prescriptions for cannabis-based treatments with a tetrahydrocannabinol content of more than 1% without the need for an exceptional licence from the Federal Office of Public Health.
If the draft amendment is approved, the Narcotics Act's existing prohibition on placing medical cannabis on the Swiss market would be repealed.
The cultivation, processing and trading of medicinal cannabis would thereby become legal within the framework of a control system managed by Swissmedic.(1)
For further information on this topic please contact Andreas Wildi at Walder Wyss by telephone (+41 58 658 20 00) or email (email@example.com). The Walder Wyss website can be accessed at www.walderwyss.com.
(1) For further information, see here.
The materials contained on this website are for general information purposes only and are subject to the disclaimer.
ILO is a premium online legal update service for major companies and law firms worldwide. In-house corporate counsel and other users of legal services, as well as law firm partners, qualify for a free subscription.